Anemia management in chronic kidney disease: Bursting the hemoglobin bubble

Annals of Internal Medicine

Volumn 153, Issue 1, 2010, Pages 53-55

  Weiner, Daniel E ^a   Miskulin, Dana C ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CHRONIC KIDNEY DISEASE; EDITORIAL; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; BLOOD; CHRONIC KIDNEY FAILURE; METABOLISM; NOTE;

ANEMIA; ERYTHROPOIETIN, RECOMBINANT; HEMATINICS; HEMOGLOBINS; HUMANS; RENAL INSUFFICIENCY, CHRONIC;

EID: 77955869114     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-153-1-201007060-00250     Document Type: Editorial

References (20)

1. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med. 1989;111:992-1000. [PMID: 2688507]
2. Goodnough LT, Strasburg D, Riddell J 4th, Verbrugge D, Wish J. Has recombinant human erythropoietin therapy minimized red-cell transfusions in hemodialysis patients? Clin Nephrol. 1994;41:303-7. [PMID: 8050211]
3. Ibrahim HN, Ishani A, Foley RN, Guo H, Liu J, Collins AJ. Temporal trends in red blood transfusion among US dialysis patients, 1992-2005. Am J Kidney Dis. 2008;52:1115-21. [PMID: 18823686]
4. Nissenson AR, Korbet S, Faber M, Burkart J, Gentile D, Hamburger R, et al. Multicenter trial of erythropoietin in patients on peritoneal dialysis. J Am Soc Nephrol. 1995;5:1517-29. [PMID: 7703390]
5. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ. 1990;300:573-8. [PMID: 2108751]
6. Revicki DA, Brown RE, Feeny DH, Henry D, Teehan BP, Rudnick MR, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis. 1995;25:548-54. [PMID: 7702049]
7. Rice L, Alfrey CP. The negative regulation of red cell mass by neocytolysis: physiologic and pathophysiologic manifestations. Cell Physiol Biochem. 2005;15:245-50. [PMID: 16037689] (Pubitemid 41022626)
8. Vaziri ND, Zhou XJ, Naqvi F, Smith J, Oveisi F, Wang ZQ, et al. Role of nitric oxide resistance in erythropoietin-induced hypertension in rats with chronic renal failure. Am J Physiol. 1996;271:E113-22. [PMID: 8760088]
9. Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol. 2008;141:14-31. [PMID: 18324962]
10. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584-90. [PMID: 9718377]
11. Vlagopoulos PT, Tighiouart H, Weiner DE, Griffith J, Pettitt D, Salem DN, et al. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol. 2005;16:3403-10. [PMID: 16162813]
12. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008;74:791-8. [PMID: 18596733]
13. Thamer M, Zhang Y, Kaufman J, Cotter D, Dong F, Hernán MA. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA. 2007;297:1667-74. [PMID: 17440144]
14. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071-84. [PMID: 17108342]
15. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085-98. [PMID: 17108343]
16. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, et al. Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data. Cochrane Database Syst Rev. 2009:CD007303. [PMID: 19588423]
17. Pfeffer MA. Critical missing data on erythropoiesis-stimulating agents in CKD: first beat placebo [Editorial]. Am J Kidney Dis. 2008;51:366-9. [PMID: 18295051]
18. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019-32. [PMID: 19880844]
19. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010;153:23-33.
20. Prisant A. TREAT versus treatment: a patient's view of a scientific interpretation. Am J Kidney Dis. 2010;55:A31-2. [PMID: 20189046]